T
Tomasz J. Janicki
Publications - 31
Citations - 283
Tomasz J. Janicki is an academic researcher. The author has contributed to research in topics: Progressive disease & Radiation therapy. The author has an hindex of 9, co-authored 29 publications receiving 234 citations.
Papers
More filters
Journal ArticleDOI
The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma
TL;DR: The results suggest that ANP shows efficacy and acceptable tolerability profile in patients with RPDIPG, and responding patients experienced improved quality of life.
Journal ArticleDOI
Long-term survival (>13 years) in a child with recurrent diffuse pontine gliosarcoma: a case report.
TL;DR: This report indicates that it is possible to obtain long-term survival of a child with a highly aggressive recurrent GS with diffuse pontine involvement with a currently available investigational treatment.
Journal ArticleDOI
A Phase II Study of Antineoplastons A10 and AS2-1 in Children with High-Grade Glioma. Final Report (Protocol BT-06), and Review of Recent Trials
TL;DR: It is concluded that antineoplastons show efficacy with an acceptable profile in this cohort of patients with recurrent high-grade glioma and there was improvement of quality of life in patients who had objective response.
Journal ArticleDOI
A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Recurrent, Refractory or Progressive Primary Brain Tumors—Final Report (Protocol BT-22)
Stanislaw R. Burzynski,Tomasz J. Janicki,Gregory S. Burzynski,Ania Marszalek,Sheldon Brookman +4 more
TL;DR: This Phase II study evaluated the efficacy and safety of Antineoplastons A10 and AS2-1 (ANP) in children who developed progression during standard treatment and found the best results were obtained in the DIPG and AA groups.
Journal ArticleDOI
Recurrent Glioblastoma Multiforme—A Strategy for Long-Term Survival
TL;DR: Phase I/II clinical trials with ANP and PB in combination with targeted agents, bevacizumab (BVZ), pazopanib, dasatinib and everolimus in patients with RGBM after failure of standard surgery, radiation therapy and chemotherapy are proposed to evaluate survival, response and toxicity in these patients.